{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:37:57Z","timestamp":1790105877296,"version":"4.0.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00392-023-02163-x","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T09:03:56Z","timestamp":1677143036000},"page":"653-655","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tafamidis for cardiac transthyretin amyloidosis: application in a real-world setting in Germany"],"prefix":"10.1007","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0920-6094","authenticated-orcid":false,"given":"Caroline","family":"Morbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Papagianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ihne-Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Cejka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Steinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Fette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Geier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Frantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"issue":"11","key":"2163_CR1","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379(11):1007\u20131016","journal-title":"N Engl J Med"},{"key":"2163_CR2","unstructured":"https:\/\/www.pfizer.de\/sites\/default\/files\/FI-22926.pdf."},{"key":"2163_CR3","first-page":"88","volume":"248","author":"G Fette","year":"2018","unstructured":"Fette G, Kaspar M, Liman L et al (2018) Exporting data from a clinical data warehouse. Stud Health Technol Inform 248:88\u201393","journal-title":"Stud Health Technol Inform"},{"issue":"10","key":"2163_CR4","first-page":"159","volume":"117","author":"S Ihne","year":"2020","unstructured":"Ihne S, Morbach C, Sommer C et al (2020) Amyloidosis-the diagnosis and treatment of an underdiagnosed disease. Dtsch Arztebl Int 117(10):159\u2013166","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"2163_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","volume":"110","author":"A Yilmaz","year":"2021","unstructured":"Yilmaz A, Bauersachs J, Bengel F et al (2021) Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol 110(4):479\u2013506","journal-title":"Clin Res Cardiol"},{"issue":"6","key":"2163_CR6","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","volume":"23","author":"R Rettl","year":"2022","unstructured":"Rettl R, Mann C, Duca F et al (2022) Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging 23(6):767\u2013780","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2163_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-022-02035-w","author":"B Chamling","year":"2022","unstructured":"Chamling B, Bietenbeck M, Korthals D et al (2022) Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging. Clin Res Cardiol. https:\/\/doi.org\/10.1007\/s00392-022-02035-w","journal-title":"Clin Res Cardiol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02163-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-023-02163-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02163-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T10:21:06Z","timestamp":1713435666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-023-02163-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2163"],"URL":"https:\/\/doi.org\/10.1007\/s00392-023-02163-x","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"assertion":[{"value":"8 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CM reports research cooperation with the University of W\u00fcrzburg and Tomtec Imaging Systems funded by a research grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy, Germany; advisory and speakers honoraria as well as travel grants from Amgen, Tomtec, Orion Pharma, Alnylam, AKCEA, Pfizer, Boehringer Ingelheim, SOBI, Alexion, Janssen, and EBR Systems; principal investigator in trials sponsored by Alnylam, Bayer and AstraZeneca; financial support from the interdisciplinary center for clinical research\u2014IZKF W\u00fcrzburg (advanced clinician-scientist program). AP received research funding grand from Pfizer, consulting fees from Pfizer, Alnylam, Aksea and Swedish Orphan Biovitrum GmbH-Sobi, financial support for attending meetings and\/or travel from Alnylam, Akcea and Pfizer. Aikaterini Papagianni is also PI in ION-682884-CS3 study. SI received financial reimbursement for consulting, advisory board activities, speaker honoraries and\/or travel support to attend scientific meetings by Akcea Therapeutics Inc., Alnylam Pharmaceuticals Inc., Pfizer Pharmaceuticals, Janssen-Cilag GmbH, and Takeda, and further research funding from Pfizer Pharmaceuticals and Akcea Therapeutics Inc.. An internship was supported by ONLUS. She was fellow of the local Clinician Scientist program of the IZKF W\u00fcrzburg. VC received financial support and travel funding for attendance of scientific congresses from Alnylam Pharmaceuticals Inc. and Boehringer Ingelheim. StS is supported by the CHFC W\u00fcrzburg, and by the German Federal Ministry of Education and Research (BMBF). He has received consultancy and lecture fees as well as reimbursement of travel costs from AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Pfizer, and Servier. The other authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}